Sequana Medical announces Annual General Meeting of Shareholders on 25 May 2023
April 25, 2023 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION25 April 2023, 07:00 am CEST Publication of Annual Report 2022 Ghent, Belgium – 25 April 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or...
SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 15.78 MILLION IN AN EQUITY PLACEMENT
April 25, 2023 00:15 ET
|
Sequana Medical NV
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED...
SEQUANA MEDICAL LAUNCHES EQUITY PLACEMENT AND AMENDS CERTAIN EXISTING LOAN AGREEMENTS
April 24, 2023 11:00 ET
|
Sequana Medical NV
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED...
Sequana Medical announces submission of Investigational New Drug (IND) application for DSR® 2.0 for treatment of congestive heart failure
April 03, 2023 01:00 ET
|
Sequana Medical NV
PRESS RELEASE Ghent, Belgium – 03 April 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease,...
Sequana Medical announces additional patents for DSR® in China and the United States
March 22, 2023 02:00 ET
|
Sequana Medical NV
PRESS RELEASE Ghent, Belgium – 22 March 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease,...
Sequana Medical announces positive results from CHIHUAHUA, Phase 1 clinical trial of second-generation DSR product for congestive heart failure
March 01, 2023 01:00 ET
|
Sequana Medical NV
PRESS RELEASE Phase 1 clinical trial (CHIHUAHUA) demonstrates that single dose of second-generation DSR product (DSR 2.0) is safe and well-tolerated, and indicates a compelling dosing profileOn...
Sequana Medical announces results of Extraordinary General Meeting of Shareholders
February 10, 2023 12:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION10 February 2023, 18:00 CET Ghent, Belgium – 10 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in...
Sequana Medical announces 2022 Full Year Results and 2023 Outlook
February 09, 2023 01:02 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION09 February 2023, 07:00 CEST alfapump® – successful primary endpoint read-out of North American pivotal POSEIDON study / PMA1 filing planned for H2 2023DSR®...
Transparency Notifications from Shareholders
February 09, 2023 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION09 February 2023, 07:00 am CEST Ghent, Belgium – 09 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer...
Sequana Medical announces the successful completion of pre-clinical studies with its second-generation DSR product for congestive heart failure
February 08, 2023 01:00 ET
|
Sequana Medical NV
PRESS RELEASE Data from GLPi animal studies demonstrate safety of second-generation DSRii product (DSR 2.0)Data from Phase 1 study of DSR 2.0 in Mexico (CHIHUAHUA) and INDiii filing to US FDA...